Orion b Aktie
| 69,45EUR | -0,10EUR | -0,14% |
WKN DE: A0J3QM / ISIN: FI0009014377
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 3 355 | 3 527 | 3 632 | 3 712 | 4 029 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,31 | 0,38 | 0,33 | 0,42 | 0,47 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 690 | 879 | 825 | 1 016 | 1 344 |
| Summe Anlagevermögen | 424 | 625 | 621 | 619 | 666 |
| Summe Aktiva | 1 114 | 1 504 | 1 446 | 1 636 | 2 010 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 366 | 596 | 556 | 631 | 725 |
| Summe Eigenkapital | 748 | 908 | 890 | 1 005 | 1 285 |
| Summe Passiva | 1 114 | 1 504 | 1 446 | 1 636 | 2 010 |
Adresse
| Orionintie 1A, 02200 Espoo | |
| Telefon | +358 (10) 4261 |
| Internet | http://www.orionpharma.com |
Management
|
Aino Anna Liisa Hurme
President & Chief Executive Officer |
|
Ari Tapio Lehtoranta
Independent Director |
|
Eija Ronkainen
Independent Director |
|
Henrik Stenqvist
Independent Director |
|
Hilpi Rautelin
Vice Chairman |
|
Juhani Kankaanpaa
Senior Vice President-Global Operations |
|
Julia Macharey
Senior Executive Vice President-People & Culture |
|
Karen Lykke Sörensen
Independent Director |
|
Kari Jussi Aho
Independent Director |
|
Maziar Mike Doustdar
Independent Director |
|
Mikko Kemppainen
Secretary & General Counsel |
|
Outi Vaarala
SVP-Innovative Medicines, Research & Development |
|
René Lindell
Chief Financial Officer |
|
Satu Maarit Ahomäki
Senior VP-Generics & Consumer Health |
|
Sinikka Markkula
Chief Information Officer |
|
Tuukka Hirvonen
Head-Investor Relations |
|
Veli-Matti Johannes Mattila
Chairman |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.